SNBL USA Announces Facility Expansion

Everett, WA - Sept 1, 2006 - SNBL USA, one of the nation’s leading preclinical testing companies, today announced it has recently increased its capacity, in effect doubling its Everett facility to 225,000 sq. ft. This expansion brings SNBL USA additional laboratory, research and resource space.

"We are very excited with our recent expansion progress," said Ryoichi Nagata, SNBL USA CEO and Chairman. "Not only have we doubled our overall facility here on the Everett campus, but we have increased our research and resource capacity by 50%, and tripled the size of our Laboratory Services in actual lab space and manpower capability."

Steven Meyer, SNBL USA President, goes on to say, "This expansion broadens the scope of our overall service capabilities. For example, we now have dedicated space and scientific teams in the areas of virology, molecular biology, and immune assessments. We are confident that this recent expansion and continuing growth will allow SNBL USA to provide even faster start times for preclinical studies that is necessary to satisfy the drug development industry."

About SNBL USA

SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. If you are interested in SNBL USA, please contact us at (425) 407-0121 or info@snblusa.com.